Neutralizing Antibody Assays for SARS-CoV-2 Variant Studies
With COVID-19 vaccines now widely available, case numbers in many areas are falling. But the question remains: How long does vaccine-induced immunity last? Measuring isotype-specific antibodies against SARS-CoV-2 and the effectiveness of neutralizing antibodies against variants can help us better understand the duration and breadth of the humoral response. These data are critical to aid public health researchers and inform development decisions for vaccines and therapeutics. Read about the new Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel.
Advantages of Multiplexing with Bio-Plex Assays
The Bio-Plex Assay development process is designed to produce high performance multiplex assays. We prioritize sensitivity, broad dynamic range, reproducibility, and shorter incubation times to get you meaningful results faster. Watch this video to learn more about our SMARTS approach to assay development.
Multiplex Immunoassays in the Race for a COVID-19 Vaccine
In vaccine development, safety and efficacy are critical. Recent studies have shown that multiplex immunoassays offer a flexible way to monitor immune responses. With the ever-increasing pressure on scientists to develop a practical COVID-19 vaccine, multiplex immunoassays stand out as a proven tool.